PPH vs PJP: Which Pharma ETF Should You Own Now?
Two major pharmaceutical ETFs go head-to-head. Here's how to pick the right one for your portfolio.
If you're hunting for pharma exposure, two ETFs keep coming up: VanEck's PPH and Invesco's PJP. Both give you a slice of the drug industry, but they're built differently — and that difference matters when you're putting real money to work.
PPH tracks a market-cap-weighted index of global pharmaceutical companies, meaning the biggest names dominate your holdings. That's a more passive, diversified approach. PJP, on the other hand, uses an equal-weight methodology focused on U.S.-listed pharma stocks, giving smaller players more room to move the needle on your returns.
Read more Micron Stock: Why $1,750 Could Be the New Price Target →
The construction difference alone should guide your decision. If you want blue-chip, large-cap stability with some international flavor, PPH is your lane. If you believe mid-tier U.S. drug makers are where the alpha lives, PJP gives those names actual weight in the portfolio instead of burying them.
Cost and liquidity matter too. Before you pull the trigger on either fund, check the expense ratio and average daily volume. A cheaper ETF that trades thinly can eat your returns through wide bid-ask spreads — especially if you're trading size or moving in and out frequently.
Bottom line: neither ETF is universally better. Your choice comes down to whether you want global mega-cap pharma or a more democratized U.S.-focused bet. Size up your thesis, check the holdings overlap with what you already own, and trade accordingly. Continue reading at Yahoo Finance.
